Evgen Pharma plc “Update re SFX-01 Data at ECTRIMS 2016”

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has told DirectorsTalk that the abstract and poster relating to the results of its preclinical study of SFX-01 in various models of the relapsing remitting form of multiple sclerosis are now available on the Company’s website.

The preclinical study focused on the comparison of SFX-01 with dimethyl fumarate, the active principle in BG-12, which is marketed as Tecfidera®.

In addition to this completed preclinical study, Evgen Pharma has ongoing clinical studies of SFX-01.  A Phase II study in subarachnoid haemorrhage is currently underway and the first patient is expected to be dosed shortly in a Phase II study in breast cancer.

The preclinical study data in multiple sclerosis are being presented this week in London at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

The poster, entitled Efficacy of SFX-01, a sulforaphane-based drug in experimental autoimmune encephalomyelitis, is available at this link:http://evgen.com/wp-content/uploads/2016/09/ECTRIMS-2016-POSTER-.pdf

The abstract of the poster is at this link: http://evgen.com/wp-content/uploads/2016/09/ECTRIMS-2016-ABSTRACT.pdf

As stated in the announcement on 8 September 2016, the Company is conducting a commercial appraisal of the potential of SFX-01 in multiple sclerosis and will give a further update to shareholders later this year.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Evgen Pharma Plc

    More articles like this

    Evgen Pharma Plc

    21 Health Benefits of Broccoli

    Are you looking for a vegetable to spice up your diet in a healthy way? If yes, then broccoli, also called Brassica oleracea italica, is the vegetable you want. The dark green crucifer is not only

    Evgen Pharma Plc

    12 things that are actually tied to breast cancer

    According to the Centres for Disease Control and Prevention (CDC), breast cancer is the most common cancer in women. In the US, one in eight women will develop breast cancer during her lifetime. Those statistics sound

    Evgen Pharma Plc

    10 subtle signs of breast cancer

    A diagnosis of breast cancer can be terrifying. According to the CDC, Breast cancer is the most common cancer in American women of any race or ethnicity. Though the statistics might be scary, catching breast cancer

    Evgen Pharma Plc

    Evgen Pharma plc Investor Presentation in Manchester

    Evgen Pharma plc (LON: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that Steve Franklin, the Company’s CEO, will be presenting tomorrow evening at a ShareSoc Growth

    Evgen Pharma Plc

    ‘I never knew men could get breast cancer’

    Moses Musonga never thought men could get breast cancer until he was diagnosed with the disease in 2013. The 67-year-old Kenyan told the BBC that he was profoundly shock when doctors told him in 2013 that

    Evgen Pharma Plc

    Male Breast cancer:What are the signs and how to check?

    Breast cancer is more commonly associated with women more than with men, affecting approximately one in eight women in their lifetimes. However, men can still be diagnosed with breast cancer, albeit in far rarer circumstances. While